Equities

Oxford Biodynamics PLC

Oxford Biodynamics PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)8.00
  • Today's Change-0.10 / -1.23%
  • Shares traded528.73k
  • 1 Year change-51.15%
  • Beta1.5836
Data delayed at least 20 minutes, as of May 03 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oxford BioDynamics Plc is a United Kingdom-based biotechnology company developing medicine tests for immune health based on the EpiSwitch 3D genomics platform. The Company is primarily engaged in the commercialization of proprietary molecular diagnostics products and biomarker research and development. Its products include EpiSwitch CiRT, EpiSwitch CST and EpiSwitch Explorer. The EpiSwitch CiRT is a blood test, which predicts an individual patient’s therapeutic response to checkpoint inhibitor immunotherapy. The EpiSwitch CST is a blood test for the prediction of COVID-19 severity in any adult. The EpiSwitch Explorer is a microarray kit for high-throughput, high-resolution 3D genome profiling. The EpiSwitch platform offers reproducibly translating 3D genome regulation for clinical application. This platform provides a portfolio of clinical smart tests based on EpiSwitch technology.

  • Revenue in GBP (TTM)510.00k
  • Net income in GBP-10.83m
  • Incorporated2007
  • Employees45.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Synairgen plc0.00-9.99m12.49m30.00--0.7821-----0.0496-0.04960.000.07930.00----0.00-41.40-54.75-48.86-60.72-------83,247.62----0.00------63.74--0.00--
Incanthera PLC0.00-1.48m12.91m8.00---------0.0192-0.01920.00-0.00860.00----0.00-373.20-101.74---132.88---------------------36.11------
Genincode PLC1.72m-6.73m13.05m28.00--1.48--7.61-0.0703-0.07030.01790.04970.16816.362.8861,285.71-65.92---72.37--47.55---392.31--5.85--0.0632--23.92---34.21------
Provexis plc598.08k-496.59k14.71m2.00--14.67--24.59-0.0002-0.00020.00030.00040.67173.042.95299,040.00-55.78-48.82-41.86-33.6846.7286.14-83.03-97.641.96--0.00---8.5110.58-71.79------
Oncimmune Holdings PLC1.15m-6.15m17.05m56.00--25.96--14.80-0.08590.05070.01590.00890.12391.080.5941---66.15---131.46--68.75---533.94--3.75-1.960.8897--------------
LungLife AI Inc36.67k-4.32m17.15m15.00--1.05--467.70-0.1693-0.16930.00140.24750.0038--0.28312,444.72-44.11---50.09--100.00---11,767.39------0.0419--91.67--28.83------
Destiny Pharma PLC0.00-5.66m17.39m20.00--1.89-----0.0624-0.06240.000.09650.00-------60.33-54.32-67.28-59.97--------------------13.02--35.39--
Verici DX PLC15.15k-8.94m17.57m14.00--2.31--1,159.73-0.0525-0.05250.000090.03130.0013--0.11521,009.77-77.76---92.28--84.21---59,015.79------0.0232-------36.94------
OptiBiotix Health PLC689.10k-13.17m17.63m3.00--1.75--25.58-0.1489-0.14890.00780.10290.04262.281.25229,700.00-81.3517.83-83.4318.6649.3154.87-1,911.88190.543.24-0.0890.00---79.3519.05-58.686.2830.03--
Skinbiotherapeutics PLC161.65k-2.88m18.54m11.00--4.82--114.66-0.0165-0.01650.00090.01920.05220.88710.418114,695.45-93.07-52.07-115.26-57.3362.90---1,784.70-4,694.376.48-379.780.0259--76.65---1.52--18.00--
Hemogenyx Pharmaceuticals PLC0.00-6.69m21.00m17.00--6.53-----0.0061-0.00610.000.00240.00----0.00-101.47-82.19-112.85-95.97-----------28.030.5144-------68.14--36.68--
Oxford Biodynamics PLC510.00k-10.83m24.95m45.00--2.67--48.92-0.0729-0.07290.00350.02990.03710.79870.33211,333.33-78.82-39.72-105.32-45.5252.16---2,122.75-1,324.621.72-7.500.5154--231.17-15.53-61.34---1.60--
Sareum Holdings Plc0.00-4.26m25.91m5.00--40.86-----0.0614-0.06140.000.00590.00----0.00-160.20-71.41-195.05-81.48-------19,709.24---6.610.00-------46.96------
Science in Sport PLC65.93m-7.07m28.71m158.00--0.7213--0.4354-0.0464-0.04640.42390.21840.84794.203.83417,278.50-9.09-9.69-13.75-11.9741.8847.09-10.72-11.940.6921-2.310.2825--1.9732.50-96.47--49.81--
CRUSHMETRIC Group Ltd397.80k-878.28k30.02m20.00--1.18--75.47-0.0072-0.00720.00280.10610.02557.142.6419,890.20-5.72-40.65-8.35--34.6637.39-224.56-140.540.072-14.420.0558--119.19-1.40-7.26--12.11--
Data as of May 03 2024. Currency figures normalised to Oxford Biodynamics PLC's reporting currency: UK Pound GBX

Institutional shareholders

53.79%Per cent of shares held by top holders
HolderShares% Held
Vulpes Investment Management Pte Ltd.as of 08 Apr 202429.65m14.66%
Unicorn Asset Management Ltd.as of 08 Apr 202425.13m12.42%
Arbuthnot Latham & Co. Ltd.as of 01 Apr 202418.46m9.13%
Cantor Fitzgerald Europeas of 05 Apr 20248.02m3.97%
Investec Wealth & Investment Ltd.as of 15 Jan 20247.32m3.62%
KW Investment Management Ltd.as of 01 Apr 20245.69m2.81%
Armistice Capital LLCas of 04 Feb 20224.93m2.44%
Chelverton Asset Management Ltd.as of 01 Apr 20244.33m2.14%
Hargreaves Lansdown Asset Management Ltd.as of 01 Apr 20243.54m1.75%
Canaccord Genuity Wealth Ltd.as of 01 Apr 20241.75m0.87%
More ▼
Data from 30 Sep 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.